Skip to main content
. 2024 May 16;120(12):1400–1410. doi: 10.1093/cvr/cvae109

Figure 2.

Figure 2

Patient disposition in the ORION-8 trial aOne patient from the inclisiran arm of pivotal trials ORION-9, ORION-10, and ORION-11 did not receive any injection in ORION-8. bThe primary reasons for discontinuation were ORION-3 rollover patients not offered to complete the full study period (8.3%), death (5.0%), withdrawal of consent (4.8%), lost to follow-up, mostly during the COVID-19 pandemic period (3.1%), other (2.3%), and adverse events (1.4%).